Moderna, Inc.

Moderna, Inc. is an American biotechnology company that discovers, develops, and commercializes messenger RNA (mRNA) medicines — therapeutics and vaccines that instruct the body's own cells to produce proteins with preventive or therapeutic effects — across infectious diseases, oncology, and rare diseases. Founded in 2010 and propelled to global prominence by its COVID-19 vaccine in 2020, Moderna generated $1.94 billion in revenue in fiscal 2025 and ended the first half of 2026 with $6.9 billion in cash and investments.

This is a story about a technology platform navigating the hardest transition in biotech: from a single blockbuster product during a global emergency to a diversified, sustainable commercial enterprise. Moderna's COVID franchise produced $18.4 billion in revenue in 2022 and $6.7 billion in 2023; by 2025, it had fallen to $1.8 billion as pandemic demand evaporated. The company is now funding an ambitious pipeline — a personalized cancer vaccine developed with Merck, a seasonal flu vaccine approaching its August 2026 PDUFA date, a flu+COVID combination vaccine approved in Europe, and programs in norovirus and rare disease — while simultaneously cutting costs to preserve its balance sheet.

The central tension in this file is straightforward: the pipeline must reach the market and generate meaningful revenue before the cash cushion — still substantial at $6.9 billion — is consumed by operating losses that ran at over $2 billion annually through mid-2026. If the mRNA platform delivers a second and third commercial franchise, the current enterprise value of roughly $20.7 billion will look prescient. If the pipeline disappoints, the equity is largely a wasting cash pile.